- Home
- PUMP vs KARD Comparison
PUMP vs KARD Comparison
Compare PUMP & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PUMP | KARD |
|---|---|---|
| Founded | 2007 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PUMP | KARD |
|---|---|---|
| Price | $7.25 | $12.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $16.00 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 4.1M | 600.4K |
| Earning Date | 10-28-2026 | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,158,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.07 | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.91 | $12.23 |
| 52 Week High | $18.50 | $27.00 |
Technical Indicators
Market Signals| Indicator | PUMP | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 21.73 | 35.50 |
| Support Level | N/A | $12.23 |
| Resistance Level | $12.29 | $15.93 |
| Average True Range (ATR) | 0.46 | 1.32 |
| MACD | -0.09 | 0.08 |
| Stochastic Oscillator | 7.62 | 13.24 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.